Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma

Hideaki Shiraishi, Yutaka Fujiwara, Takanori Kakuya, Koji Tsuta, Noriko Motoi, Nami Miura, Yukio Watabe, Shun Ichi Watanabe, Rintaro Noro, Kengo Nagashima, Wilber Huang, Tesshi Yamada, Hisao Asamura, Yuichiro Ohe, Kazufumi Honda

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Aim: Although several clinical trials demonstrated the benefits of platinum-combination adjuvant chemotherapy for stage II-IIIA lung adenocarcinoma, predictive biomarkers for the efficacy of such therapy have not yet been identified. We evaluated protein overexpression of actinin-4 as a predictive biomarker of the efficacy of adjuvant chemotherapy in resected lung adenocarcinoma. Materials & methods: We measured actinin-4 protein levels in patients with completely resected stage II-IIIA lung adenocarcinoma using immunohistochemistry and then retrospectively compared survival between adjuvant chemotherapy and observation groups. Results: A total of 148 eligible patients were classified into actinin-4 positive or negative cases by immunohistochemistry. In the former, patients with adjuvant chemotherapy survived significantly longer than those with observation (hazard ratio [HR]: 0.307; p = 0.028). But, no significant survival benefit was noted with adjuvant chemotherapy (HR: 0.926; p = 0.876) in the latter. Conclusion: This marker could predict the efficacy of adjuvant chemotherapy for resected lung adenocarcinoma patients.

Original languageEnglish
Pages (from-to)721-731
Number of pages11
JournalBiomarkers in Medicine
Volume11
Issue number9
DOIs
Publication statusPublished - 2017 Sep

Keywords

  • actinin-4 (ACTN4)
  • adjuvant chemotherapy
  • predictive biomarker

ASJC Scopus subject areas

  • Drug Discovery
  • Clinical Biochemistry
  • Biochemistry, medical

Fingerprint Dive into the research topics of 'Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma'. Together they form a unique fingerprint.

  • Cite this

    Shiraishi, H., Fujiwara, Y., Kakuya, T., Tsuta, K., Motoi, N., Miura, N., Watabe, Y., Watanabe, S. I., Noro, R., Nagashima, K., Huang, W., Yamada, T., Asamura, H., Ohe, Y., & Honda, K. (2017). Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma. Biomarkers in Medicine, 11(9), 721-731. https://doi.org/10.2217/bmm-2017-0150